Small molecule · Inhibitor of glutamate and voltage-dependent sodium channels · developed by Biohaven
Troriluzole is a prodrug form of riluzole that is converted to active riluzole following oral administration. It inhibits glutamate release and inactivates voltage-dependent sodium channels, reducing glutamatergic neurotransmission. It is studied in spinocerebellar ataxias and obsessive-compulsive disorder.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04708834 | Phase 3 | Obsessive Compulsive Disorder | Terminated | BHVN |
| NCT03701399 | Phase 3 | Spinocerebellar Ataxias | Active not recruiting | BHVN |
| NCT06529146 | N/A | Spinocerebellar Ataxias | Active not recruiting | BHVN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Spinocerebellar Ataxia Type 1Spinocerebellar Ataxia Type 10Spinocerebellar Ataxia Type 2Spinocerebellar Ataxia Type 3Spinocerebellar Ataxia Type 6Spinocerebellar Ataxia Type 7Spinocerebellar Ataxia Type 8Spinocerebellar AtaxiasObsessive Compulsive Disorder
Updated Oct 3, 2026. Something wrong or missing? Report it on the BHVN page.
See BHVN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BHVN catalysts and pipeline →